Index
1 Market Overview
1.1 Product Overview and Scope of Antibody Therapeutics and Blood Antibody Therapeutics
1.2 Classification of Antibody Therapeutics and Blood Antibody Therapeutics by Type
1.2.1 Overview: Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Type in 2021
1.2.3 IgG1
1.2.4 IgG4
1.2.5 Others
1.3 Global Antibody Therapeutics and Blood Antibody Therapeutics Market by Application
1.3.1 Overview: Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Autoimmune
1.3.3 Tumor
1.3.4 Others
1.4 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size & Forecast
1.5 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast by Region
1.5.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Region, (2017-2022)
1.5.3 North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Prospect (2017-2028)
1.5.4 Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Prospect (2017-2028)
1.5.6 South America Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Antibody Therapeutics and Blood Antibody Therapeutics Market Drivers
1.6.2 Antibody Therapeutics and Blood Antibody Therapeutics Market Restraints
1.6.3 Antibody Therapeutics and Blood Antibody Therapeutics Trends Analysis
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
2.1.4 Roche Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Roche Recent Developments and Future Plans
2.2 Abbvie
2.2.1 Abbvie Details
2.2.2 Abbvie Major Business
2.2.3 Abbvie Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
2.2.4 Abbvie Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Abbvie Recent Developments and Future Plans
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business
2.3.3 Johnson & Johnson Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
2.3.4 Johnson & Johnson Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Johnson & Johnson Recent Developments and Future Plans
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business
2.4.3 Bristol-Myers Squibb Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
2.4.4 Bristol-Myers Squibb Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.5 Novartis
2.5.1 Novartis Details
2.5.2 Novartis Major Business
2.5.3 Novartis Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
2.5.4 Novartis Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Novartis Recent Developments and Future Plans
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business
2.6.3 Merck Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
2.6.4 Merck Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Merck Recent Developments and Future Plans
2.7 Alexion Pharmaceuticals
2.7.1 Alexion Pharmaceuticals Details
2.7.2 Alexion Pharmaceuticals Major Business
2.7.3 Alexion Pharmaceuticals Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
2.7.4 Alexion Pharmaceuticals Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Alexion Pharmaceuticals Recent Developments and Future Plans
2.8 Takeda
2.8.1 Takeda Details
2.8.2 Takeda Major Business
2.8.3 Takeda Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
2.8.4 Takeda Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Takeda Recent Developments and Future Plans
2.9 Amgen
2.9.1 Amgen Details
2.9.2 Amgen Major Business
2.9.3 Amgen Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
2.9.4 Amgen Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Amgen Recent Developments and Future Plans
2.10 Biogen
2.10.1 Biogen Details
2.10.2 Biogen Major Business
2.10.3 Biogen Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
2.10.4 Biogen Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Biogen Recent Developments and Future Plans
2.11 UCB
2.11.1 UCB Details
2.11.2 UCB Major Business
2.11.3 UCB Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
2.11.4 UCB Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 UCB Recent Developments and Future Plans
2.12 Eli Lilly and Company
2.12.1 Eli Lilly and Company Details
2.12.2 Eli Lilly and Company Major Business
2.12.3 Eli Lilly and Company Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
2.12.4 Eli Lilly and Company Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Eli Lilly and Company Recent Developments and Future Plans
2.13 AstraZeneca
2.13.1 AstraZeneca Details
2.13.2 AstraZeneca Major Business
2.13.3 AstraZeneca Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
2.13.4 AstraZeneca Antibody Therapeutics and Blood Antibody Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 AstraZeneca Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Antibody Therapeutics and Blood Antibody Therapeutics Players Market Share in 2021
3.2.2 Top 10 Antibody Therapeutics and Blood Antibody Therapeutics Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Antibody Therapeutics and Blood Antibody Therapeutics Players Head Office, Products and Services Provided
3.4 Antibody Therapeutics and Blood Antibody Therapeutics Mergers & Acquisitions
3.5 Antibody Therapeutics and Blood Antibody Therapeutics New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Market Share by Type (2017-2022)
4.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Application (2017-2022)
5.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Type (2017-2028)
6.2 North America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application (2017-2028)
6.3 North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country
6.3.1 North America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Country (2017-2028)
6.3.2 United States Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
6.3.3 Canada Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
6.3.4 Mexico Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Type (2017-2028)
7.2 Europe Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application (2017-2028)
7.3 Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country
7.3.1 Europe Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Country (2017-2028)
7.3.2 Germany Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
7.3.3 France Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
7.3.5 Russia Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
7.3.6 Italy Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Type (2017-2028)
8.2 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application (2017-2028)
8.3 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Region
8.3.1 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Region (2017-2028)
8.3.2 China Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
8.3.3 Japan Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
8.3.4 South Korea Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
8.3.5 India Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
8.3.7 Australia Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Type (2017-2028)
9.2 South America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application (2017-2028)
9.3 South America Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country
9.3.1 South America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Country (2017-2028)
9.3.2 Brazil Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
9.3.3 Argentina Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Type (2017-2028)
10.2 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application (2017-2028)
10.3 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country
10.3.1 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Country (2017-2028)
10.3.2 Turkey Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
10.3.4 UAE Antibody Therapeutics and Blood Antibody Therapeutics Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
List of Tables
Table 1. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Antibody Therapeutics and Blood Antibody Therapeutics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million) by Region (2017-2022)
Table 5. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Region (2023-2028)
Table 6. Roche Corporate Information, Head Office, and Major Competitors
Table 7. Roche Major Business
Table 8. Roche Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
Table 9. Roche Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Abbvie Corporate Information, Head Office, and Major Competitors
Table 11. Abbvie Major Business
Table 12. Abbvie Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
Table 13. Abbvie Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 15. Johnson & Johnson Major Business
Table 16. Johnson & Johnson Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
Table 17. Johnson & Johnson Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 19. Bristol-Myers Squibb Major Business
Table 20. Bristol-Myers Squibb Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
Table 21. Bristol-Myers Squibb Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Novartis Corporate Information, Head Office, and Major Competitors
Table 23. Novartis Major Business
Table 24. Novartis Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
Table 25. Novartis Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Merck Corporate Information, Head Office, and Major Competitors
Table 27. Merck Major Business
Table 28. Merck Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
Table 29. Merck Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Alexion Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 31. Alexion Pharmaceuticals Major Business
Table 32. Alexion Pharmaceuticals Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
Table 33. Alexion Pharmaceuticals Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Takeda Corporate Information, Head Office, and Major Competitors
Table 35. Takeda Major Business
Table 36. Takeda Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
Table 37. Takeda Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Amgen Corporate Information, Head Office, and Major Competitors
Table 39. Amgen Major Business
Table 40. Amgen Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
Table 41. Amgen Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Biogen Corporate Information, Head Office, and Major Competitors
Table 43. Biogen Major Business
Table 44. Biogen Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
Table 45. Biogen Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. UCB Corporate Information, Head Office, and Major Competitors
Table 47. UCB Major Business
Table 48. UCB Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
Table 49. UCB Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors
Table 51. Eli Lilly and Company Major Business
Table 52. Eli Lilly and Company Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
Table 53. Eli Lilly and Company Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 55. AstraZeneca Major Business
Table 56. AstraZeneca Antibody Therapeutics and Blood Antibody Therapeutics Product and Solutions
Table 57. AstraZeneca Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 59. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 60. Breakdown of Antibody Therapeutics and Blood Antibody Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 61. Antibody Therapeutics and Blood Antibody Therapeutics Players Head Office, Products and Services Provided
Table 62. Antibody Therapeutics and Blood Antibody Therapeutics Mergers & Acquisitions in the Past Five Years
Table 63. Antibody Therapeutics and Blood Antibody Therapeutics New Entrants and Expansion Plans
Table 64. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million) by Type (2017-2022)
Table 65. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Share by Type (2017-2022)
Table 66. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Forecast by Type (2023-2028)
Table 67. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application (2017-2022)
Table 68. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Forecast by Application (2023-2028)
Table 69. North America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 70. North America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 71. North America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 72. North America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 73. North America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 74. North America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 75. Europe Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 76. Europe Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 77. Europe Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 78. Europe Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 79. Europe Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 80. Europe Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 81. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 82. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 83. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 84. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 85. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 86. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 87. South America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 88. South America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 89. South America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 90. South America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 91. South America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 92. South America Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 93. Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 94. Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 95. Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 96. Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 97. Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 98. Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Antibody Therapeutics and Blood Antibody Therapeutics Picture
Figure 2. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Type in 2021
Figure 3. IgG1
Figure 4. IgG4
Figure 5. Others
Figure 6. Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Application in 2021
Figure 7. Autoimmune Picture
Figure 8. Tumor Picture
Figure 9. Others Picture
Figure 10. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 11. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Region (2017-2028)
Figure 13. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Region in 2021
Figure 14. North America Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Europe Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. South America Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Middle East and Africa Antibody Therapeutics and Blood Antibody Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Antibody Therapeutics and Blood Antibody Therapeutics Market Drivers
Figure 20. Antibody Therapeutics and Blood Antibody Therapeutics Market Restraints
Figure 21. Antibody Therapeutics and Blood Antibody Therapeutics Market Trends
Figure 22. Roche Recent Developments and Future Plans
Figure 23. Abbvie Recent Developments and Future Plans
Figure 24. Johnson & Johnson Recent Developments and Future Plans
Figure 25. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 26. Novartis Recent Developments and Future Plans
Figure 27. Merck Recent Developments and Future Plans
Figure 28. Alexion Pharmaceuticals Recent Developments and Future Plans
Figure 29. Takeda Recent Developments and Future Plans
Figure 30. Amgen Recent Developments and Future Plans
Figure 31. Biogen Recent Developments and Future Plans
Figure 32. UCB Recent Developments and Future Plans
Figure 33. Eli Lilly and Company Recent Developments and Future Plans
Figure 34. AstraZeneca Recent Developments and Future Plans
Figure 35. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Share by Players in 2021
Figure 36. Antibody Therapeutics and Blood Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 37. Global Top 3 Players Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share in 2021
Figure 38. Global Top 10 Players Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share in 2021
Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 40. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Share by Type in 2021
Figure 41. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Share Forecast by Type (2023-2028)
Figure 42. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Share by Application in 2021
Figure 43. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Share Forecast by Application (2023-2028)
Figure 44. North America Antibody Therapeutics and Blood Antibody Therapeutics Sales Market Share by Type (2017-2028)
Figure 45. North America Antibody Therapeutics and Blood Antibody Therapeutics Sales Market Share by Application (2017-2028)
Figure 46. North America Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Country (2017-2028)
Figure 47. United States Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Canada Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Mexico Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Europe Antibody Therapeutics and Blood Antibody Therapeutics Sales Market Share by Type (2017-2028)
Figure 51. Europe Antibody Therapeutics and Blood Antibody Therapeutics Sales Market Share by Application (2017-2028)
Figure 52. Europe Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Country (2017-2028)
Figure 53. Germany Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. France Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. United Kingdom Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Russia Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Italy Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Sales Market Share by Type (2017-2028)
Figure 59. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Sales Market Share by Application (2017-2028)
Figure 60. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Region (2017-2028)
Figure 61. China Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Japan Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South Korea Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. India Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Southeast Asia Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Australia Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. South America Antibody Therapeutics and Blood Antibody Therapeutics Sales Market Share by Type (2017-2028)
Figure 68. South America Antibody Therapeutics and Blood Antibody Therapeutics Sales Market Share by Application (2017-2028)
Figure 69. South America Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Country (2017-2028)
Figure 70. Brazil Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Argentina Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Middle East and Africa Antibody Therapeutics and Blood Antibody Therapeutics Sales Market Share by Type (2017-2028)
Figure 73. Middle East and Africa Antibody Therapeutics and Blood Antibody Therapeutics Sales Market Share by Application (2017-2028)
Figure 74. Middle East and Africa Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Country (2017-2028)
Figure 75. Turkey Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. UAE Antibody Therapeutics and Blood Antibody Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Methodology
Figure 79. Research Process and Data Source